Bristol-Myers Squibb

BMYleader

Bristol-Myers Squibb is a global biopharmaceutical company with leading franchises in oncology and cardiovascular medicine. Eliquis is the world's best-selling oral anticoagulant and Opdivo is a top-selling cancer immunotherapy.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($45.0B)

靜態數據（加載即時財務…）

Oncology (42%)

Cardiovascular (33%)

Immunology (15%)

Other (10%)

業務部門構成與主要客戶

產品詳情

Eliquis30%

Blood thinner for stroke prevention in atrial fibrillation

Opdivo25%

Immuno-oncology checkpoint inhibitor for multiple cancer types

Revlimid15%

Treatment for multiple myeloma and other blood cancers

Other Specialty30%

Cardiovascular, immunology, and fibrosis therapeutics pipeline

供應鏈關係

競爭對手

Johnson & Johnson

Oncology, immunology drugs

影響: Major pharma competitor

主要客戶

UnitedHealth Group

Formulary drug placements

影響: $3B+ annually

The Cigna Group

Drug coverage via Express Scripts

影響: $2B+ annually

宏觀與市場背景

헬스케어行業新聞

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化劑

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

點擊「取得 AI 分析」以獲得 Bristol-Myers Squibb 的 AI 供應鏈分析。

企業資訊

總部

New York, New York, USA

成立時間

1887

員工人數

34,000+

官網

bms.com

行業概況 — 헬스케어

行業新聞